Our grouping. This page groups the registry's lead sponsor names by company — our grouping, not the registry's. It can be wrong or incomplete: an acquired company whose name never mentions its owner may be missing. Use “Something wrong?” under any name below to correct it.
Tell us about a missing company
Santhera Pharmaceuticals clinical trials
The registry lists 29 studies whose lead sponsor is Santhera Pharmaceuticals or one of 1 company grouped under it. 1 are recruiting or about to start. Per ClinicalTrials.gov, last updated Apr 23, 2026.
Keep track of what changes. Save the Santhera Pharmaceuticals studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesRegistry sponsor names on this page
Each name exactly as ClinicalTrials.gov lists it, and how it relates to Santhera Pharmaceuticals.
- Santhera Pharmaceuticals27 studiesSame company
Something wrong?
- Juvantia Pharma Ltd2 studies →Acquired — became part of Santhera Pharmaceuticals, Oct 5, 2009 · source ↗
Something wrong?
Studies
Recruiting first, then most recently updated. Showing 29 of 29.
- Expanded Access Protocol for Boys With Duchenne Muscular DystrophyAvailableNCT03863119
- A Study on Safety and Effectiveness of Long-term Treatment With Vamorolone in Boys With Duchenne Muscular DystrophyActive, not recruitingNCT06713135Phase 4
- Evaluation of Vamorolone CYP3A4 Induction on Midazolam (a Sensitive CYP 3A4 Substrate) PharmacokineticsCompletedNCT06689527Phase 1
- A Study to Assess Vamorolone in Boys Ages 2 to <4 Years and 7 to <18 Years With Duchenne Muscular Dystrophy (DMD)CompletedNCT05185622Phase 2
- Evaluation of Vamorolone Mineralocorticoid Receptor Antagonism in Healthy SubjectsCompletedNCT06649409Phase 1
- Study to Assess the Efficacy, Safety and Tolerability of Idebenone in the Treatment of Friedreich's AtaxiaCompletedNCT00537680Phase 3
- Study to Assess the Safety and Tolerability of Idebenone in the Treatment of Friedreich's Ataxia PatientsCompletedNCT00697073Phase 3
- Expanded Access Program for Idebenone in Patients With Leber's Hereditary Optic Neuropathy Who Completed the LEROS StudyNo longer availableNCT04381091
- Expanded Access Program for Idebenone in Participants With Duchenne Muscular Dystrophy (DMD)No longer availableNCT03433807
- Study to Assess the Efficacy and Safety of Raxone in LHON PatientsCompletedNCT02774005Phase 4
- A Phase III Double-blind Study With Idebenone in Patients With Duchenne Muscular Dystrophy (DMD) Taking Glucocorticoid SteroidsTerminatedNCT02814019Phase 3
- Phase III Study With Idebenone in Patients With Duchenne Muscular Dystrophy (SIDEROS-E)TerminatedNCT03603288Phase 3
- Clinical Study to Investigate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of POL6014 in Patients With CFCompletedNCT03748199Phase 1/2
- Congenital Muscular Dystrophy Ascending Multiple Dose Cohort Study Analyzing Pharmacokinetics at Three Dose Levels In Children and Adolescents With Assessment of Safety and Tolerability of Omigapil (CALLISTO)CompletedNCT01805024Phase 1
- Post Authorisation Safety Study With Raxone in LHON PatientsCompletedNCT02771379
- Historical Case Record Survey of Visual Acuity Data From Patients With Leber's Hereditary Optic Neuropathy (LHON)CompletedNCT02796274
- Long-Term Safety and Tolerability of Idebenone in Friedreich's Ataxia Patients (MICONOS Extension)CompletedNCT00993967Phase 3
- A Study to Assess the Potential for Pre-systemic Inhibition of CYP3A by Idebenone Using Midazolam as a SubstrateCompletedNCT02887443Phase 1
- A Study of Efficacy, Safety and Tolerability of Idebenone in the Treatment of Friedreich's Ataxia (FRDA) PatientsCompletedNCT00905268Phase 3
- Patient Reported Outcomes in Friedreich's Ataxia Patients After Withdrawal From Treatment With Idebenone (PROTI)CompletedNCT01303406Phase 3
- Phase III Study of Idebenone in Duchenne Muscular Dystrophy (DMD)CompletedNCT01027884Phase 3
- Study With Idebenone in Patients With Chronic Vision Loss Due to Leber's Hereditary Optic Neuropathy (LHON)WithdrawnNCT01495715Phase 3
- Leber Hereditary Optic Neuropathy (LHON) Historical Case Record SurveyCompletedNCT01892943
- RHODOS Follow-up Single-visit StudyCompletedNCT01421381
- Study to Assess Efficacy,Safety and Tolerability of Idebenone in the Treatment of Leber's Hereditary Optic NeuropathyCompletedNCT00747487Phase 2
- Efficacy and Tolerability of Idebenone in Boys With Cardiac Dysfunction Associated With Duchenne Muscular DystrophyCompletedNCT00654784Phase 2
- Long-term Safety, Tolerability and Efficacy of Idebenone in Duchenne Muscular Dystrophy (DELPHI Extension)CompletedNCT00758225Phase 2
- Safety and Efficacy Study of Fipamezole in Treatment of Motor Dysfunctions in Parkinson's DiseaseCompletedNCT00559871Phase 2
Sponsor listed in the registry: Juvantia Pharma Ltd · First submitted before Juvantia Pharma Ltd became part of Santhera Pharmaceuticals
- Fipamezole in Neurogenic Orthostatic HypotensionStatus unknownNCT00758849Phase 2
Sponsor listed in the registry: Juvantia Pharma Ltd · First submitted before Juvantia Pharma Ltd became part of Santhera Pharmaceuticals